ANTCHAIN
1.11.2021 07:05:09 CET | Business Wire | Press release
Blockchain Association Singapore (BAS) today signed a Memorandum of Understanding (MOU) with AntChain, the flagship technology brand of Ant Group to form close collaborations to promote and drive further blockchain adoption and innovation in Singapore and ASEAN.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211031005054/en/
Under the partnership, BAS and AntChain will co-organize events and programs in Singapore and China to raise further awareness of blockchain, to drive industry adoption and promote positive impact through continuous innovation, and to strengthen the ecosystem of talents and empower the community through training and knowledge sharing.
The MOU with BAS is the first such industry partnership for AntChain outside China.
Commenting on the partnership, Mr Chia Hock Lai, Co-Chairman, BAS said, “We recognize AntChain’s market leadership as demonstrated through its innovative solutions and a vast range of industry applications and use cases from supply chain finance, cross border traceability of high value goods, to content and copyright protection. Thus, it is an absolute pleasure to collaborate closely with AntChain, which we believe will bring valuable technical know-how and industry experience to BAS’s members and partners in Singapore and the region. Together, more blockchain innovations can be fostered to contribute to the growth and transformation of businesses and industries.”
Mr Derrick Loi, General Manager of International Business, Intelligent Technology at Ant Group, echoed, “We firmly believe that partnerships and collaborations stimulate innovation. We are committed to working closely with industry partners such as BAS to explore new synergies, resolve pain points faced by businesses, and uncover greater value for a broader group of customers in today's digital economy. We very much look forward to enabling trusts in use cases such as digital trade, thereby connecting B2B2C with industry specific applications of enterprise blockchain, secure computing, IoT, eKYC, and other innovative technologies.”
In recent months, BAS has also formed partnerships with Alliance of Blockchain Industry (ABI) and the Energy Research Institute of the Nanyang Technological University respectively, to collaborate in various aspects to promote blockchain application, research and talent development.
In June, AntChain launched a developer community support program at its first developer conference. To date, the community has attracted over 330 institutional partners and nearly 10,000 developers, who together have created over 30 innovative industry applications. Now AntChain's wide portfolio of technologies and solutions have been deployed in more than 50 use cases, typically involving multi-party collaborations.
+++
About Blockchain Association Singapore
The Blockchain Association Singapore (BAS) seeks to empower its members and the community to leverage blockchain and scalable technologies for business growth and transformation. The Association is designed to be an effective platform for members to engage with multiple stakeholders – both regional and international – to discover solutions and promote best practices in a collaborative, open, and transparent manner.
It aims to promote blockchain literacy and build a strong talent pipeline for the digital economy in Singapore. BAS also aims to accelerate the development of blockchain companies operating in or entering into Singapore, and their subsequent integration and acceleration into the Singapore blockchain ecosystem.
For more information, please visit https://singaporeblockchain.org/ .
About AntChain
As the flagship technology brand of Ant Group, AntChain is dedicated to building the foundations of trust with innovative technologies including blockchain, the internet of things, data analytics, and intelligent risk management. It aims to develop mutually trusted, highly efficient industry based solutions to enable trust between enterprises and their customers in the new digital economy, support industry collaboration and value creation. AntChain was ranked first in China's blockchain-as-a-service market in 2020, according to market intelligence provider IDC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211031005054/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom